Heena Lodha
Long/short equity, small-cap, healthcare, oil & gas

Charles River Laboratories: A Well-Positioned CRO Due To Blossom In Pre-Clinical Services

Sometimes, you don't need too many reasons to invest in a stock, only one strong point is enough to make the investment, and Charles River Laboratories (CRL) is a good example of this.

After a challenging period from 2008 through 2011, share performance of the CROs has rebounded nicely over the last several years, with the momentum continuing thus far in 2014. Big pharma companies are under pressure to cut costs to offset sales lost to patent expiration. So, to reduce cash expenditures, pharma companies are moving toward CROs to outsource R&D models. This provides an excellent opportunity to the CRO industry, which has grown 10.2% to $13.6 billion since 2011. Behind solid quarterly earnings results for 2013

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details